A five-year study on subjects who had only the cancerous portion of their prostate glands destroyed shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function.
A study by University of Arizona Health Sciences researchers found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a synergistic treatment approach.
The phase III VERIFY trial, in which phlebotomy-dependent patients with polycythemia vera were randomized to treatment with either rusfertide (PTG-300) or placebo, as an add-on to standard of care treatment, met its primary endpoint of proportion of patients achieving response.
A new analysis by the International Agency for Research on Cancer and collaborators evaluates the latest and future global burden of female breast cancer in about 50 countries worldwide.
A protein designed by Cedars-Sinai Cancer investigators can cross the protective blood-brain barrier safely and deliver therapy directly into cancerous tumor cells, a preclinical study shows.
Researchers at Fox Chase Cancer Center recently published two reviews on the complex role of AKT, also known as protein kinase B, in the development and treatment of cancer.
Multidrug resistance in cancer can be overcome by combining a drug that blocks a key enzyme with another anticancer drug, according to a study in preclinical models led by researchers at UT Southwestern Medical Center.
A study led by the Joe C. Wen School of Population & Public Health at the University of California, Irvine, has revealed possible links between exposure to per- and polyfluoroalkyl substances in drinking water and an increased risk of certain childhood cancers.
Researchers at the University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate designed to stimulate immune-mediated eradication of tumors.
UCLA scientists have identified a potential new strategy for treating glioblastoma, the deadliest form of brain cancer, by reprogramming aggressive cancer cells into harmless ones.
